Highlights Castle Biosciences, Inc.

Equities

CSTL

US14843C1053

Market Closed - Nasdaq Other stock markets 03:59:47 2024-06-04 pm EDT			5-day change	1st Jan Change
23.54 ^USD	+0.60%		-4.04%	+9.08%

May. 30	Castle Biosciences, Inc. Announces to Present New Data Related to Its DecisionDx-Melanoma and DecisionDx-UM Tests At the 2024 American Society of Clinical Oncology	CI
May. 29	Castle Biosciences, Inc. Announces That New Publication Shows DecisionDx®-SCC Identifies High-Risk Squamous Cell Carcinoma Patients Who Are Likely to Benefit from Adjuvant Radiation Therapy and Those Who Can Consider Deferring Treatment Based on Biological Risk of Metastasis	CI

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Castle Biosciences, Inc. Announces to Present New Data Related to Its DecisionDx-Melanoma and DecisionDx-UM Tests At the 2024 American Society of Clinical Oncology	May. 30	CI
Castle Biosciences, Inc. Announces That New Publication Shows DecisionDx®-SCC Identifies High-Risk Squamous Cell Carcinoma Patients Who Are Likely to Benefit from Adjuvant Radiation Therapy and Those Who Can Consider Deferring Treatment Based on Biological Risk of Metastasis	May. 29	CI
Castle Biosciences, Inc. Announces New Data from A Study Further Confirming the Performance of its DecisionDx-UM Test as A Robust Independent Predictor of Metastasis-Free Survival in Patients Diagnosed with UM	May. 08	CI
Earnings Flash (CSTL) CASTLE BIOSCIENCES Posts Q1 Revenue $73M, vs. Street Est of $66.2M	May. 02	MT
Castle Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 02	CI
Castle Biosciences, Inc. Revises Earnings Guidance for the Full Year of 2024	May. 02	CI
Castle Biosciences, Inc. Announces Share New Data At the 20Th European Association of Dermato-Oncology Congress	Apr. 04	CI
Castle Biosciences, Inc. Announces the Publication of an Expert Consensus Article in the Journal of Clinical and Aesthetic Dermatology	Mar. 19	CI
Castle Biosciences, Inc. Announces the Publication of a New Multi-Center Performance Study of its DecisionDx-SCC Risk Stratification Test	Mar. 07	CI
Earnings Flash (CSTL) CASTLE BIOSCIENCES Posts Q4 Revenue $66.1M, vs. Street Est of $61.2M	Feb. 28	MT
Castle Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 28	CI
Castle Biosciences, Inc. Provides Revenue Guidance for the Full Year 2024	Feb. 28	CI
Castle Biosciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 28	CI
Castle Biosciences, Inc. Presents Data Supporting the Utility of Its Tests in the Clinical Care of Patients with Skin Cancers at the 2024 Winter Clinical Dermatology Conference - Hawaii	Jan. 14	CI
Castle Biosciences Sees 53% Growth in Annual Revenue in 2023	Jan. 08	MT
Castle Biosciences, Inc. Provides Revenue Guidance for the Year 2023	Jan. 07	CI
Castle Biosciences, Inc. Announces Data from A Single-Site, Open-Label Study Demonstrating the Consistent Impact of Idgenetix®? on Medication Response and Remission Rates in Patients with Major Depressive Disorder	Nov. 08	CI
Castle Biosciences, Inc. Announces Early Exploratory Study Data for Potential Development of A Complementary Test to Accompany Decisiondx®-Um That Could Aid in the Early Detection of Uveal Melanomas	Nov. 03	CI
Earnings Flash (CSTL) CASTLE BIOSCIENCES Posts Q3 Revenue $61.5M, vs. Street Est of $48.6M	Nov. 02	MT
Castle Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 02	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Castle Biosciences, Inc.

Equities

CSTL

US14843C1053

Highlights

Filters